ENDRA Life Sciences (NDRA) Cash from Investing Activities (2017 - 2026)

ENDRA Life Sciences (NDRA) has reported Cash from Investing Activities for 10 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to $2.2 million in Q2 2026; TTM through Jun 2026 was -$332895.0, a 1826.48% decrease from a year earlier, with the FY2025 full-year figure at -$3.0 million, down 23479.87% from the prior year.
• Cash from Investing Activities was $2.2 million for Q2 2026 at ENDRA Life Sciences, up from $450000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $2.2 million in Q2 2026 and troughed at -$3.0 million in Q4 2025.
• A 5-year average of -$49189.1 and a median of -$20538.0 in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 98.56% in 2022 and surged 2704.17% in 2026, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$38563.0 in 2022, then soared by 105.91% to $2279.0 in 2023, then surged by 382.67% to $11000.0 in 2024, then tumbled by 27372.73% to -$3.0 million in 2025, then surged by 173.9% to $2.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $2.2 million (Q2 2026), $450000.0 (Q1 2026), and -$3.0 million (Q4 2025), per Business Quant data.